Acomplia (rimonabant), marketed by Sanofi-Aventis is a selective CB1 endocannabinoid receptor antagonist for the treatment of obesity. The mechanism for blocking endogenous cannabinoid binding to neuronal CB1 receptors.

What is endocannabinoid system?
The endocannabinoid system in the part of the brains, metabolism, …